Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation.
A new, worldwide coalition of plasma companies seeking to develop and deliver a hyperimmune immunoglobulin therapy for fighting COVID-19 takes the view that many hands make light work.
A new, worldwide coalition of plasma companies seeking to develop and deliver a hyperimmune immunoglobulin therapy for fighting COVID-19 takes the view that many hands make light work.